ImmunityBio, Inc. (IBRX)
| Market Cap | 5.44B |
| Revenue (ttm) | 82.56M |
| Net Income (ttm) | -348.62M |
| Shares Out | 984.97M |
| EPS (ttm) | -0.42 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 182,288,197 |
| Open | 4.70 |
| Previous Close | 3.95 |
| Day's Range | 4.38 - 5.58 |
| 52-Week Range | 1.83 - 5.58 |
| Beta | -0.04 |
| Analysts | Strong Buy |
| Price Target | 11.50 (+108.33%) |
| Earnings Date | Mar 2, 2026 |
About IBRX
ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company’s platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA... [Read more]
Financial Performance
In 2024, ImmunityBio's revenue was $14.75 million, an increase of 2270.58% compared to the previous year's $622,000. Losses were -$413.56 million, -29.09% less than in 2023.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for IBRX stock is "Strong Buy." The 12-month stock price target is $11.5, which is an increase of 108.33% from the latest price.
News
ImmunityBio, Inc. (IBRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
ImmunityBio, Inc. (IBRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
ImmunityBio Stock Soars On Cancer Trial Progress, FDA Timeline
ImmunityBio Inc. (NASDAQ: IBRX) stock has surged more than 100% year to date after the upbeat fourth-quarter preliminary results and trial data.
ImmunityBio's 700% Revenue Boom Becomes Citadel's Latest I‑Told‑You‑So
Hedge funds don't need headlines to move — they need inflection points. ImmunityBio Inc (NASDAQ: IBRX) just delivered one.
ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced updated efficacy and safety results from the ongoing QUILT-106 clinica...
ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced an update on the status of enrollment in its randomized registrational trial in BCG-naïve non-muscle-invasive bla...
This Biotech Stock Is Up 100% This Year. Why It's Soaring Again Today.
The shares have climbed on every trading day so far in 2026. The streak looks set to continue.
ImmunityBio: Why I Am Upgrading To A Buy For 2026
ImmunityBio is upgraded to Buy for 2026, reflecting improving Anktiva data and potential label expansions in NMIBC and NSCLC. IBRX reported 2025 product revenue of $113m, up 700% year-on-year, but los...
ImmunityBio Clocks 700% Revenue Surge In 2025 From Lead Bladder Cancer Drug
ImmunityBio, Inc. (NASDAQ: IBRX) shares are up on Thursday as the company is reporting continued execution and sales momentum, with a significant increase in preliminary net product revenue.
ImmunityBio Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue—a 700% increase year-over-year
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a vertically-integrated commercial stage biotechnology company, announced today preliminary select operational results for the f...
Saudi FDA Grants Accelerated Approval to ImmunityBio's ANKTIVA® In Combination with Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug Authority (SFDA) has granted accelerated ...
Saudi FDA Grants Accelerated Approval to ImmunityBio's ANKTIVA® for Non-Muscle Invasive Bladder Cancer with Carcinoma In-Situ
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug Authority (SFDA) has granted approval of ...
ImmunityBio Announces Positive Results Demonstrating ANKTIVA® as a Lymphocyte Stimulating Agent in Combination With Checkpoint Inhibitors in Non-Small Cell Lung Cancer
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results from its ANKTIVA (nogapendekin alfa inbakicept) clinica...
NantWorks and ImmunityBio Announce Inaugural U.S.-Saudi Biotech Alliance Summit to Advance Immunotherapy 2.0 and Global Health Security
CULVER CITY, Calif.--(BUSINESS WIRE)--NantWorks, LLC, and ImmunityBio, Inc. (NASDAQ: IBRX), today announced the inaugural U.S.-Saudi Biotech Alliance Summit, to be held in conjunction with the 44th An...
ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of “100 Most Influential People in Oncology in 2025”
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that OncoDaily has recognized Dr. Patrick Soon-Shiong as being one of ...
ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus Calme...
ImmunityBio Moves Closer To EU Approval For Bladder Cancer Therapy
The European Medicines Agency has recommended granting a conditional marketing authorization for ImmunityBio, Inc.‘s (NASDAQ: IBRX) Anktiva (nogapendekin alfa inbakicept) in combination with Bacillus ...
ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio (NASDAQ: IBRX), a leading immunotherapy company, announced today that the European Medicines Agency has recommended granting a conditional marketing a...
A Second Anktiva Approval Could Be The Catalyst ImmunityBio Needs
ImmunityBio delivered strong 3Q25 results, with Anktiva driving 434% YoY product revenue growth and a narrowed operating loss. IBRX's cash position improved to $257.8 million, providing a 3-4 quarter ...
ImmunityBio: Checking The Boxes Of A True Commercial-Stage Biotech
ImmunityBio shows strong commercial momentum with ANKTIVA, reporting significant revenue growth and improved net loss in Q3. IBRX pipeline progress includes promising data in glioblastoma, NSCLC, non-...
New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations
CULVER CITY, Calif.--(BUSINESS WIRE)--A new U.S. survey conducted by The Harris Poll on behalf of ImmunityBio, Inc. (NASDAQ: IBRX) reveals that many people living with non-muscle invasive bladder canc...
Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced its financial results for the fiscal quarter and nine months ended September 30...
Looking For The Next Beyond Meat? Here Are The Top 10 Most Shorted Stocks
Investors searching for the next Beyond Meat, Inc. (NYSE:BYND) — the latest poster child for explosive short squeezes — are eyeing the most shorted stocks as potential candidates for outsized rallies.
ImmunityBio: A Small Bet Is Warranted
ImmunityBio should be rated as a speculative buy for aggressive investors only, offering significant upside despite ongoing dilution and cash burn concerns. Anktiva, IBRX's lead therapy, is ramping up...
ImmunityBio: Still Too Early To Judge Anktiva, Although Clock Is Ticking
I maintain a Hold rating on ImmunityBio as Anktiva shows strong NMIBC data but the commercial uptake remains slow and uncertain. IBRX's Q2 revenues rose to $26.4M, but accumulated losses and lack of f...